Closing Thoughts with Patient Cases: Disease Control With Modern Therapies
April 2nd 2025A panelist discusses how contemporary therapeutic approaches enable successful management of atopic dermatitis through examination of real-world patient cases that demonstrate effective disease control strategies using the latest treatment options.
Factors that Impact Therapy Decisions for Atopic Dermatitis (AD)
April 2nd 2025A panelist discusses how treatment selection for atopic dermatitis is influenced by multiple considerations including disease severity, patient age, affected body regions, comorbidities, previous treatment responses, and patient preferences.
Other Topical Options to Treat Atopic Dermatitis (AD): Topical JAK Inhibitors and AhR Agonists
April 2nd 2025A panelist discusses how topical JAK inhibitors and AhR agonists represent emerging therapeutic approaches for atopic dermatitis that target specific inflammatory pathways to provide effective symptom relief with distinct mechanisms of action.
Streamlining Atopic Dermatitis (AD) Diagnosis and Treatment in Primary Care
April 2nd 2025A panelist discusses how primary care practitioners can implement efficient diagnostic protocols and treatment pathways to better manage atopic dermatitis patients within the constraints of busy clinical settings.
Atopic Dermatitis (AD) Across Ages: Identifying and Treating Flares in Children and Adults
April 2nd 2025A panelist discusses how healthcare providers can effectively identify and manage atopic dermatitis flares across different age groups, highlighting the unique challenges and treatment approaches for both pediatric and adult populations.
Educating Patients and Providers: Key Takeaways for Better VMS Management
March 28th 2025Panelists discuss how providers should actively screen for vasomotor symptoms (VMS), especially given the lengthy wait times to see specialists, emphasizing that education for both patients and health care providers is essential for timely intervention and effective management.
Liver Safety and Monitoring in VMS Treatment
March 28th 2025Panelists discuss how fezolinetant and elinzanetant can cause liver-related adverse events requiring careful monitoring for drug-induced liver injury, noting that patients typically recover after discontinuation and emphasizing that primary providers are ideally positioned to manage patients with complex comorbidities.
Beyond Hormone Therapy: Effective Alternatives for Managing Menopausal Symptoms
March 28th 2025Panelists discuss how previous therapies lacked efficacy for vasomotor symptoms, while new treatments fezolinetant and elinzanetant offer superior effectiveness, with elinzanetant specifically addressing additional symptoms beyond the primary condition.
Understanding VMS in Menopause: Prevalence and Impact
March 28th 2025Panelists discuss how vasomotor symptoms (VMS) can persist for years with variable manifestations, significantly disrupting both social and professional spheres, resulting in multibillion-dollar economic losses through decreased productivity and increased insurance costs.